Why Appen, Breville, Credit Corp, and ResMed Shares Are Storming Higher Today
Why Appen, Breville, Credit Corp, and ResMed Shares Are Storming Higher Today
The $S&P/ASX 200 (.XJO.AU)$ has run out of steam and dropped into the red. In afternoon trade, the benchmark index is down a disappointing 0.5% to 7,953.2 points.
本基金尋求於東歐地區註冊的主要權益關聯發行人的長期升值投資。$S&P/ASX 200 (.XJO.AU)$指數已經失去支撐，走入下跌區間。在下午交易中，基準指數下跌了令人失望的0.5%，跌至7953.2點。
Four ASX shares that are not letting that hold them back today are listed below. Here's why they are rising:
以下四隻ASX股票今日漲幅強勁，詳情如下：
The Appen share price is up 23% to 53 cents. This follows the release of a quarterly update from the struggling artificial intelligence data services company this morning. Appen revealed that its revenue was down 16% on the prior corresponding period. However, this was due to the loss of Google as a customer. If you exclude Google, Appen's revenue would have been up 16% for the period. Management also reported improvements in its profitability and continues to target positive cash EBITDA during the second half of FY 2024.
Appen股價上漲23%，達到53美分。這是在今天早上這家陷入困境的人工智能數據服務公司發佈季度更新之後發生的。Appen披露，其營業收入與去年同期相比下降了16%。然而，這是由於谷歌不再是客戶。如果將谷歌排除在外，Appen的營業收入將在這一期間上漲16%。管理層還報告了其盈利能力的改善，並繼續針對2024財年下半年實現正現金EBITDA。
The Breville Group share price is up 3.5% to $29.19. This is despite there being no news out of the appliance manufacturer on Tuesday. However, it is worth noting that analysts at Goldman Sachs reiterated their buy rating and $30.00 price target on Breville's shares yesterday. The broker commented: "We see 2H24 sales +9.3% YoY (+3% vs Factset) on first-time US sell-in to Target, improving HSD EMEA sales and -1% APAC from sluggish ANZ though strong S. Korea."
Breville Group股價上漲了3.5%，至29.19美元。這是儘管該電器製造商週二沒有任何消息。然而，值得注意的是，高盛的分析師在昨天重申了對Breville股票的買入評級和30.00美元的價格目標。經紀人評論說：“我們預計2H24銷售額同比增長9.3%（與Factset相比增長3%），首次銷售至Target，歐中非高速增長，但因澳新寡淡而使亞太地區下降1%。”
The Credit Corp share price is up almost 7% to $16.22. Investors have been buying the debt collection company's shares today following the release of its FY 2024 results. Although Credit Corp posted a sizeable profit decline and slashed its dividend, the market appears to be focusing more on its guidance for FY 2025. The midpoint of its net profit after tax guidance range represents an increase of 17% on what was achieved in FY 2024.
Credit Corp股價上漲近7%，至16.22美元。今天，投資者正在購買這家催收公司的股票，這是因爲該公司發佈了2024財年的業績。儘管Credit Corp發佈了大幅盈利下滑和削減股息，但市場似乎更關注其2025財年的指引。其淨利潤預期範圍的中點相對於2024財年實現的利潤增長了17%。
The ResMed share price is up almost 3% to $31.44. This follows a strong night of trade for the sleep disorder treatment company's shares on Wall Street. Investors were snapping up ResMed's shares on the belief that a selloff on Friday was an overreaction. As we covered here, the company's shares dropped after a medical device company with a similar customer base downgraded its revenue guidance. This sparked fears that weight loss drugs were having an impact. However, it seems that this downgrade was due to company specific issues and not because of Ozempic et all.
瑞思邁股價上漲近3%，至31.44美元。這是在睡眠障礙治療公司的股票在華爾街表現強勁的一夜之後發生的。投資者正在搶購瑞思邁的股票，因爲他們相信上週五的拋售行爲是過度反應。正如我們在這裏報道的那樣，這家醫療器械公司由於類似的客戶群體降低了其營收指引，導致其股票下跌。這激起人們對減肥藥概念的擔憂。然而，似乎這種降級是由於公司特定問題而不是由於歐塞普等藥物引起的。